Trial Profile

A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 06 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TG 4010 (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Erlotinib; Gemcitabine; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms TIME
Sponsors Transgene

06 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database
28 Jul 2020 This trial is completed in UK (Global End Date: 05 Jul 2016), according to European Clinical Trials Database record.
30 Oct 2017 According to a Transgene media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) Meeting 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com